A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

References

• Weidmann E, Gramatzki M, Wilhelm M, Mitrou PS. Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting. Ann Oncol 2004;15:369–374.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474–2479.
   PubMed Web of Science ®Google Scholar
• Greer JP. Therapy of peripheral T/NK neoplasms. Hematol Am Soc Hematol Educ Program 2006:331–337.
   PubMedGoogle Scholar
• Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994;47:313–317.
   PubMed Web of Science ®Google Scholar
• Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 2006;82:807–812.
   Google Scholar
• Ginaldi L, De Martinis M, Matutes E, et al Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185–191.
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, et al A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920–2924.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, Baccarani M. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005;90:702–703.
   PubMed Web of Science ®Google Scholar
• Dearden CE, Matutes E, Cazin B, et al High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721–1726.
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R, et al Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267–4272.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Patti C, et al Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316–2323.
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS, et al Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007;60:129–134.
   PubMed Web of Science ®Google Scholar
• Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P. Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma. Blood 2006;108(Suppl. 1):286b (Abstract 4740).
   PubMed Web of Science ®Google Scholar
• Ravandi-Kashani F, Kantarjian H, Faderl S, et al Combination therapy with alemtuzumab and pentostatin is effective and has acceptable toxicity in patients with T-lymphoid neoplasms. Blood 2006;108(Suppl. 1):330b (Abstract 4971).
   Google Scholar
• Scarisbrick JJ, Child FJ, Clift A, et al A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 2001;144:1010–1015.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kotani T, Nakamura Y, Ueda M. Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. Int J Hematol 2006;83:450–453.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Keating M, Coutré S, Rai K, et al Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004;4:220–227.
   PubMedGoogle Scholar
• O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006;7:125–130.
   PubMedGoogle Scholar
• Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H. Strategies in the management of alemtuzumab-related side effects. Semin Oncol 2006;33(Suppl. 5):S29–S35.
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H, et al Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005;23:7024–7031.
   PubMed Web of Science ®Google Scholar
• Lin TS, Donohue KA, Lucas MS, et al Consolidation therapy with subcutaneous (sc) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB study 10101. Blood 2007;110(Suppl. 1):216a (Abstract 755).
   Google Scholar
• O'Brien SM, Kantarijan HM, Thomas DA, et al Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657–2663.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Coenen JL, Boers JE, van Imhoff GW, Rosati S. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 2008;112:1039–1041.
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004;104:655–658.
   PubMed Web of Science ®Google Scholar
• Lundin J, Kennedy B, Dearden C, Dyer MJ, Osterborg A. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood 2005;105:4148–4149.
   PubMed Web of Science ®Google Scholar